Highest development stage: Phase 3

Development status: Discontinued for iv use

Gram-negative activity

Propensity to select resistant bacteria Yes 10-10

Mechanism of Action/Target pathogen: Hospital-acquired bacterial pneumonia/ ventilator-associated bacterial pneumonia (caused by Pseudomonas aeruginosa)

Reason dropped: Latent nephrotoxicity; Polyphor continued preclinical development of inhalation formulation and been granted clinical trial in UK on 2020

Additional information: Failed in Phase 3 due to nephrotoxicity, developed for inhalation therapy